Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7426 to 7440 of 7707 results

  1. Venous thromboembolism (VTE) - ximelagatran [ID396]

    Discontinued [GID-TAG378]

    Technology appraisal guidance
    Discontinued

  2. Intensity modulated radiotherapy for breast cancer [ID16]

    Discontinued [GID-TAG390]

    Technology appraisal guidance
    Discontinued

  3. Intensity modulated radiotherapy for prostate cancer [ID17]

    Discontinued [GID-TAG396]

    Technology appraisal guidance
    Discontinued

  4. Dasatinib for the treatment of acute lymphoblastic leukaemia [ID386]

    Discontinued [GID-TAG399]

    Technology appraisal guidance
    Discontinued

  5. Thrombophilia [ID393]

    Discontinued [GID-TAG374]

    Technology appraisal guidance
    Discontinued

  6. Juvenile idiopathic arthritis - abatacept [ID27]

    Discontinued [GID-TAG402]

    Technology appraisal guidance
    Discontinued

  7. Drugs for the treatment of pulmonary arterial hypertension [ID12]

    Discontinued [GID-TAG382]

    Technology appraisal guidance
    Discontinued

  8. Atrial fibrillation - ximelagatran [ID376]

    Discontinued [GID-TAG377]

    Technology appraisal guidance
    Discontinued

  9. Diabetic retinopathy - ruboxistaurin [ID382]

    In development [GID-TAG386] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]

    In development [GID-TAG406] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Dexmedetomidine for treating agitation associated with schizophrenia TS ID 10726

    In development [GID-TA11015] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Belzutifan for previously treated advanced renal cell carcinoma [ID6154]

    In development [GID-TA11086] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375]

    In development [GID-TA11441] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Triptorelin for the adjuvant treatment of early breast cancer in premenopausal women [ID976]

    Discontinued [GID-TA11261]

    Technology appraisal guidance
    Discontinued

  15. Multiple myeloma - bortezomib (consolidation therapy) [ID529]

    Discontinued [GID-TAG320]

    Technology appraisal guidance
    Discontinued